Ginsenoside Rg3 (Shenyi Capsule) Combined with Chemotherapy for Digestive System Cancer in China: A Meta-Analysis and Systematic Review

Table 4

Sensitivity analysis via excluding the under- or overestimated trials.

Indicators		Trials	OR (95% CI)	I^2	Excluded studies [Reference]	Trials	OR (95% CI)	I^2
ORR (CRC)		3	2.43[1.06, 5.60]	57%	Zeng et al. CRC [23]	2	3.39[1.21, 9.54]	57%
DCR (CRC)		3	2.74[0.85, 8.79]	62%	Zeng et al. CRC [23]	2	4.85[2.04, 11.53]	0%
SR (1-year)		6	2.33[1.24, 4.37]	53%	Zhou et al. GC [18]	5	1.77 [1.16, 2.70]	0%
Gastrointestinal dysfunction	CRC	4	0.64 [0.36, 1.16]	0%	No statistical significance
	EC	3	0.62 [0.31, 1.22]	32%	Wang EC [25]	2	0.49 [0.27, 0.90]	0%
	LC	4	0.34[0.13, 0.92]	65%	Liu et al. LC [16]	3	0.24 [0.09, 0.58]	45%
Hepatic and renal dysfunction		7	0.79 [0.49, 1.29]	5%	Wang et al. LC [31]	5	0.54 [0.30, 0.99]	0%
					Zhao et al. LC [29]